glp-1 agonist cardiovascular outcomes Receptor Agonists for the Reduction of Atherosclerotic Risk in Patients With Type 2 Diabetes Frontiers | The benefits of
Description
Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation
A small, short study had two patients on liraglutide with positive postprandial C-peptide at baseline completely discontinued insulin treatment with good glycemic control (63)
doi: 10.1210/jendso/bvad056 191 GralskaJRanyUPolusADziewoskaAGrucaAZdzienickaAet al
K.McleanB
lixisenatide), LEADER (Liraglutide Effects and Action in Diabetes: Evaluation of cardiovascular outcome Results
Early trials, concerned about possible cardiac safety issues, were designed to ensure that GLP-1 use did not negatively impact cardiovascular outcomes
